Integral Diagnostics (IDX) Aperçu de l'action
Integral Diagnostics Limited, une société de services de santé, fournit des services d'imagerie diagnostique aux médecins généralistes, aux spécialistes médicaux, aux professionnels de la santé et à leurs patients en Australie et en Nouvelle-Zélande. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 4/6 |
| Performances passées | 3/6 |
| Santé financière | 2/6 |
| Dividendes | 2/6 |
Récompenses
Analyse des risques
IDX Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Integral Diagnostics Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | AU$2.00 |
| Plus haut sur 52 semaines | AU$3.07 |
| Plus bas sur 52 semaines | AU$1.91 |
| Bêta | 0.11 |
| Variation sur 1 mois | -5.66% |
| Variation sur 3 mois | -14.89% |
| Variation sur 1 an | -21.88% |
| Variation sur 3 ans | -39.02% |
| Variation sur 5 ans | -61.61% |
| Évolution depuis l'introduction en bourse | 9.29% |
Nouvelles et mises à jour récentes
IDX: Trimmed Outlook And Neutral Rating Will Define Near-Term Share Performance
Analysts have trimmed their price target for Integral Diagnostics to A$2.15 from A$2.49, as updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E point to a more balanced risk and reward profile following recent share price performance. What’s in the News for Integral Diagnostics No recent news stories are available for Integral Diagnostics based on the provided sources.
IDX: New Leadership And New Clinics Will Support Future Upside
Analysts have trimmed their price target for Integral Diagnostics to A$3.11 from A$3.12 as they factor in a slightly higher discount rate and marginally softer profit margin expectations, while keeping revenue growth assumptions and future P/E largely unchanged. What's in the News New Managing Director and CEO Jason Martinez is scheduled to commence on 6 August 2026, with current Managing Director and CEO Dr Ian Kadish staying on until then to support a smooth leadership transition (Key Developments).IDX: New Leadership And Clinic Expansion Will Support Future Upside
Analysts have maintained their fair value estimate for Integral Diagnostics at A$3.12 per share. This reflects unchanged views on the discount rate, revenue growth, profit margin and future P/E assumptions, and this stability has resulted in an unchanged price target.IDX: Merger Synergies And New Sites Will Drive Future Upside
Analysts have nudged their price target on Integral Diagnostics slightly lower to A$3.12 from A$3.13. This reflects minor adjustments to fair value estimates, discount rate assumptions and forward P/E expectations.IDX: Merger Synergies And New Sites Will Support Future Upside
Analysts have made a small upward adjustment to their price target for Integral Diagnostics, which now sits slightly higher in A$ terms. This reflects modest tweaks to their fair value, discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations.Recent updates
IDX: Trimmed Outlook And Neutral Rating Will Define Near-Term Share Performance
Analysts have trimmed their price target for Integral Diagnostics to A$2.15 from A$2.49, as updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E point to a more balanced risk and reward profile following recent share price performance. What’s in the News for Integral Diagnostics No recent news stories are available for Integral Diagnostics based on the provided sources.IDX: New Leadership And New Clinics Will Support Future Upside
Analysts have trimmed their price target for Integral Diagnostics to A$3.11 from A$3.12 as they factor in a slightly higher discount rate and marginally softer profit margin expectations, while keeping revenue growth assumptions and future P/E largely unchanged. What's in the News New Managing Director and CEO Jason Martinez is scheduled to commence on 6 August 2026, with current Managing Director and CEO Dr Ian Kadish staying on until then to support a smooth leadership transition (Key Developments).IDX: New Leadership And Clinic Expansion Will Support Future Upside
Analysts have maintained their fair value estimate for Integral Diagnostics at A$3.12 per share. This reflects unchanged views on the discount rate, revenue growth, profit margin and future P/E assumptions, and this stability has resulted in an unchanged price target.IDX: Merger Synergies And New Sites Will Drive Future Upside
Analysts have nudged their price target on Integral Diagnostics slightly lower to A$3.12 from A$3.13. This reflects minor adjustments to fair value estimates, discount rate assumptions and forward P/E expectations.IDX: Merger Synergies And New Sites Will Support Future Upside
Analysts have made a small upward adjustment to their price target for Integral Diagnostics, which now sits slightly higher in A$ terms. This reflects modest tweaks to their fair value, discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations.IDX: Inorganic Expansion And Merger Synergies Will Drive Future Upside
Analysts have trimmed their price target for Integral Diagnostics from around A$3.36 to about A$3.12, reflecting updated assumptions for slightly lower revenue growth, modestly softer profit margins and a reduced future P/E multiple. What's in the News Management is actively assessing M&A options and continuing to look at inorganic growth, alongside opening 3 new greenfield sites in the last quarter of the financial year in Eastwood Private Hospital (South Australia), Wangaratta (Victoria) and Maroochydore (Queensland), plus a relocation to a new facility in Launceston (Key Developments).Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success
Despite a sharp reduction in projected revenue growth, the consensus future P/E multiple for Integral Diagnostics has contracted significantly, supporting a higher analyst price target of A$3.34. Valuation Changes Summary of Valuation Changes for Integral Diagnostics The Consensus Analyst Price Target has risen from A$3.12 to A$3.34.
Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success
Synergies from the Capitol Health merger and regulation changes are expected to boost operating margins and revenue for Integral Diagnostics.Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch
Integral Diagnostics Limited ( ASX:IDX ) shareholders that were waiting for something to happen have been dealt a blow...Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being
Key Insights Integral Diagnostics will host its Annual General Meeting on 28th of November Total pay for CEO Ian Kadish...Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year
Integral Diagnostics Limited ( ASX:IDX ) has announced that on 4th of April, it will be paying a dividend ofA$0.025...These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?
While Integral Diagnostics Limited ( ASX:IDX ) might not be the most widely known stock at the moment, it saw...Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year
Integral Diagnostics Limited ( ASX:IDX ) has announced it will be reducing its dividend payable on the 4th of April to...Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Does the February share price for Integral Diagnostics Limited ( ASX:IDX ) reflect what it's really worth? Today, we...Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why
The performance at Integral Diagnostics Limited ( ASX:IDX ) has been quite strong recently and CEO Ian Kadish has...Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Rendement pour les actionnaires
| IDX | AU Healthcare | AU Marché | |
|---|---|---|---|
| 7D | 1.0% | 2.2% | -0.9% |
| 1Y | -21.9% | -8.0% | 2.3% |
Rendement vs Industrie: IDX a sous-performé le secteur Australian Healthcare qui a rapporté -8 % au cours de l'année écoulée.
Rendement vs marché: IDX a sous-performé le marché Australian qui a rapporté 2.3 % au cours de l'année écoulée.
Volatilité des prix
| IDX volatility | |
|---|---|
| IDX Average Weekly Movement | 3.7% |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 4.0% |
Cours de l'action stable: IDX n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Australian.
Volatilité au fil du temps: La volatilité hebdomadaire de IDX ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1967 | 3,000 | Ian Kadish | www.integraldiagnostics.com.au |
Integral Diagnostics Limited, une société de services de santé, fournit des services d'imagerie diagnostique aux médecins généralistes, aux médecins spécialistes, aux professionnels de la santé et à leurs patients en Australie et en Nouvelle-Zélande. La société propose des services d'imagerie par résonance magnétique, de tomographie par émission de positons, de mammographie par tomographie assistée par ordinateur, de radiologie interventionnelle, d'échographie et de radiographie (rayons X et EOS). Integral Diagnostics Limited a été fondée en 1967 et son siège social se trouve à Melbourne, en Australie.
Integral Diagnostics Limited Résumé des fondamentaux
| IDX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | AU$744.98m |
| Bénéfices(TTM) | AU$14.03m |
| Recettes(TTM) | AU$767.82m |
Le site IDX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| IDX compte de résultat (TTM) | |
|---|---|
| Recettes | AU$767.82m |
| Coût des recettes | AU$525.98m |
| Marge brute | AU$241.84m |
| Autres dépenses | AU$227.82m |
| Les revenus | AU$14.03m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
Aug 25, 2026
| Résultat par action (EPS) | 0.038 |
| Marge brute | 31.50% |
| Marge bénéficiaire nette | 1.83% |
| Ratio dettes/capitaux propres | 50.1% |
Quelles ont été les performances à long terme de IDX?
Voir les performances historiques et les comparaisonsDividendes
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/27 19:53 |
| Cours de l'action en fin de journée | 2026/06/26 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/06/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Integral Diagnostics Limited est couverte par 22 analystes. 13 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Thomas Yeo | Barrenjoey Markets Pty Limited |
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Benjamin Brayshaw | Barrenjoey Markets Pty Limited |